Wall Street Zen Upgrades SBC Medical Group (NASDAQ:SBC) to “Strong-Buy”

SBC Medical Group (NASDAQ:SBC – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Several other analysts also recently weighed in on SBC. Weiss Ratings reiterated a “sell (d+)” rating on shares of SBC Medical Group in a research report on Wednesday, August 19th. BTIG Research restated a “buy” rating and issued a $8.00 target price on shares of SBC Medical Group in a report on Thursday, August 13th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $8.50.

Get SBC Medical Group alerts:

Get Our Latest Research Report on SBC

SBC Medical Group Price Performance

Shares of NASDAQ:SBC opened at $4.75 on Friday. The company has a quick ratio of 3.27, a current ratio of 3.31 and a debt-to-equity ratio of 0.09. The stock has a market cap of $488.54 million, a PE ratio of 10.11 and a beta of 0.63. The company’s fifty day moving average is $3.66 and its 200 day moving average is $3.53. SBC Medical Group has a 52 week low of $2.78 and a 52 week high of $4.97.

SBC Medical Group (NASDAQ:SBC – Get Free Report) last released its earnings results on Thursday, August 13th. The company reported $0.10 earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.02). The company had revenue of $49.19 million during the quarter, compared to the consensus estimate of $45.37 million. SBC Medical Group had a net margin of 27.99% and a return on equity of 18.47%. Research analysts anticipate that SBC Medical Group will post 0.44 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. bought a new stake in shares of SBC Medical Group during the second quarter valued at approximately $2,846,000. Citadel Advisors LLC bought a new position in SBC Medical Group in the second quarter worth $446,000. Segall Bryant & Hamill LLC purchased a new position in SBC Medical Group during the first quarter valued at $340,000. Bank of New York Mellon Corp purchased a new position in SBC Medical Group during the second quarter valued at $83,000. Finally, Central Pacific Bank Trust Division purchased a new position in SBC Medical Group during the second quarter valued at $74,000. Hedge funds and other institutional investors own 60.82% of the company’s stock.

SBC Medical Group Company Profile

(Get Free Report)

SBC Medical Group (NASDAQ: SBC) is a Japan-based medical services and management company focused primarily on the aesthetic medicine sector. Through its affiliated medical corporations and clinic network, the company supports the operation of facilities offering cosmetic surgery, cosmetic dermatology and related elective treatments.

The company provides a range of management and operational services to affiliated clinics, including branding and marketing, staff recruitment and training, purchasing, information technology, administrative support and business consulting.

Featured Stories

• Five stocks we like better than SBC Medical Group
• NVIDIA Just Named AI’s Next Bottleneck—And These 3 Stocks Sit Right In It
• Gold Has Gone Sideways, But These 3 Stocks Haven’t
• The AI Bottleneck Is Not Chips Anymore and 3 Pipeline Stocks Are Cashing In
• These 3 Stocks Under $20 Have Wall Street Looking Past the Share Price

Receive News & Ratings for SBC Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SBC Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.